IL164154A0 - Fine particle size pioglitazone - Google Patents

Fine particle size pioglitazone

Info

Publication number
IL164154A0
IL164154A0 IL16415403A IL16415403A IL164154A0 IL 164154 A0 IL164154 A0 IL 164154A0 IL 16415403 A IL16415403 A IL 16415403A IL 16415403 A IL16415403 A IL 16415403A IL 164154 A0 IL164154 A0 IL 164154A0
Authority
IL
Israel
Prior art keywords
pioglitazone
particle size
fine particle
fine
size
Prior art date
Application number
IL16415403A
Other languages
English (en)
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL164154A0 publication Critical patent/IL164154A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL16415403A 2002-03-21 2003-03-21 Fine particle size pioglitazone IL164154A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36635202P 2002-03-21 2002-03-21
PCT/US2003/008945 WO2003080056A2 (fr) 2002-03-21 2003-03-21 Pioglitazone a particules de taille fine

Publications (1)

Publication Number Publication Date
IL164154A0 true IL164154A0 (en) 2005-12-18

Family

ID=28454788

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16415403A IL164154A0 (en) 2002-03-21 2003-03-21 Fine particle size pioglitazone

Country Status (7)

Country Link
US (1) US20050131027A1 (fr)
EP (1) EP1465628A2 (fr)
JP (1) JP2005527537A (fr)
AU (1) AU2003230719A1 (fr)
CA (1) CA2479748A1 (fr)
IL (1) IL164154A0 (fr)
WO (1) WO2003080056A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263121B2 (en) * 2004-04-14 2012-09-11 Takeda Pharmaceutical Company Limited Solid pharmaceutical preparation
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
GT200600008A (es) * 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso
US20100034885A1 (en) * 2005-06-10 2010-02-11 Combino Pharm, S.L. Formulations containing glimepiride and/or its salts
US9034381B2 (en) 2005-11-10 2015-05-19 Alphapharm Pty Ltd Process to control particle size
MY146781A (en) * 2006-05-23 2012-09-28 Takeda Pharmaceutical Oral preparation comprising pioglitazone
US20080182880A1 (en) * 2006-09-28 2008-07-31 Mailatur Sivaraman Mohan Pioglitazone composition
JP2010513324A (ja) 2006-12-21 2010-04-30 アルファファーム ピーティーワイ リミテッド 医薬化合物および医薬組成物
TR200803177A2 (tr) * 2008-05-06 2009-11-23 Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. Antihiperglisemik etkili metformîn - pioglitazon formülasyonu.
WO2012153312A1 (fr) 2011-05-11 2012-11-15 Ranbaxy Laboratories Limited Procédé pour la purification de pioglitazone
CN114452264B (zh) * 2021-12-15 2023-09-05 东药集团沈阳施德药业有限公司 一种盐酸吡格列酮胶囊及其制备方法
CN121287642A (zh) * 2025-12-15 2026-01-09 山东齐都药业有限公司 吡格列酮二甲双胍片及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010036479A1 (en) * 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
US6610272B1 (en) * 2000-05-01 2003-08-26 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6548049B1 (en) * 2000-05-01 2003-04-15 Aeropharm Technology Incorporated Medicinal aerosol formulation

Also Published As

Publication number Publication date
US20050131027A1 (en) 2005-06-16
JP2005527537A (ja) 2005-09-15
CA2479748A1 (fr) 2003-10-02
AU2003230719A1 (en) 2003-10-08
WO2003080056A3 (fr) 2003-11-13
EP1465628A2 (fr) 2004-10-13
WO2003080056A2 (fr) 2003-10-02

Similar Documents

Publication Publication Date Title
AU2003293294A8 (en) Uv-stabilised particles
GB2409180B (en) High conductivity particle filter
GB0216197D0 (en) Serrs active particles
AU2003225901A8 (en) Stabilized inorganic particles
GB2381214B (en) Particle formation
GB0223127D0 (en) nanoparticles
GB2398241B (en) Particle formation
GB2391174B (en) Particle formation
IL165033A0 (en) Bioactivation of particles
GB0223149D0 (en) Nanoparticles
EP1699435A4 (fr) Particules
AU2003902014A0 (en) Particle agglomeration
EP1402941A4 (fr) Dispositif de traitement de particules de poudre
GB0216562D0 (en) Particulate materials
AU2003230719A1 (en) Fine particle size pioglitazone
GB0324147D0 (en) Functionilisation of particles
GB0208742D0 (en) Particulate materials
AU2003237268A1 (en) Ultrafine hexagonal fertrite particles
AU2003242064A1 (en) Magnetite particles
GB0201382D0 (en) Virus-like particles
GB0300338D0 (en) Particle formation
GB0221999D0 (en) Coated metallurgical particles
GB2417218B (en) High conductivity particle filter
AU2003303064A1 (en) Fine particulate agent
GB0319782D0 (en) Clay particle size reduction